Sequoia China Leads $80M Pre-IPO Round In Chinese Biotech Firm

Login to View

BrightGene Bio-Medical Technology Co., a Chinese biopharmaceutical company, has received RMB550 million (US$80.06 million) in a pre-IPO round of financing, led by Sequoia China and HighLight Capital, with participation from GF Qianhe Investment, according to a WeChat announcement released today.

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in